
Supplemental Materials

Additional Results

Figure 1S. Consort Diagram



Participant Selection Process

Following eligibility screening, 24 CNTL and 26 TRD patients were consented via recruitment from an existing TRD database (gathered over the past 15 years at Washington University), existing psychiatric clinics at Washington University Department of Psychiatry, and through potential participant registries at Washington University School of Medicine and trial advertisement through the greater St. Louis community. Three CNTL and eleven TRD patients did not pass screening or voluntarily withdrew prior to randomization. Two TRD patients (one lost to follow-up, one terminated early due to Covid-19) and six CNTL (one lost to follow-up, one

for mask discomfort, one determined to have pre-existing psychotic disorder, one could not attend sessions, one terminated early due to Covid-19, one due to nausea/dissociative experience) withdrew from the study following the first inhalation. Despite completing all inhalation and imaging sessions, 1 CNTL participant was excluded due to use of a different scanner system and imaging protocol.

 Table 1S. Treatment-Resistant Depressed Participant Demographics

Subject ID	Sex	Race	No. of trials, current episode	No. of failed trials, lifetime	Years reported with MDD
1	Male	White/Caucasian	1	3	14
2	Female	Asian	1	3	7
3	Male	White/Caucasian	1	3	33
4	Female	Black	2	3	12
5	Female	White/Caucasian	1	9	38
6	Male	White/Caucasian	1	4	3
7	Female	White/Caucasian	2	19	39
8	Female	White/Caucasian	2	15	30
9	Female	Asian	1	3	3
10	Female	White/Caucasian	1	9	27
11	Male	White/Caucasian	1	4	19
12	Female	White/Caucasian	1	15	18
13	Female	White/Caucasian	2	14	36
14	Female	White/Caucasian	1	4	14

 Table 2S. Non-depressed Healthy Control Participant demographics

Subject ID	Sex	Race	Ethnicity
1	Female	White/Caucasian	Not Hispanic/Latino
2	Male	White/Caucasian	Not Hispanic/Latino
3	Male	Asian	Not Hispanic/Latino
4	Male	Asian	Not Hispanic/Latino
5	Female	Black	Not Hispanic/Latino
6	Female	White/Caucasian	Not Hispanic/Latino
7	Male	White/Caucasian	Hispanic/Latino
8	Female	Black	Not Hispanic/Latino
9	Male	Black	Not Hispanic/Latino
10	Female	White/Caucasian	Not Hispanic/Latino
11	Male	Black	Not Hispanic/Latino
12	Male	White/Caucasian	Not Hispanic/Latino
13	Female	White/Caucasian	Not Hispanic/Latino
14	Female	Black	Not Hispanic/Latino
15	Female	Black	Not Hispanic/Latino
16	Female	White/Caucasian	Not Hispanic/Latino

Table 3S. Differences in Network Connectivity in TRD and Healthy Controls

Seed and	Seed	Cluster Size (# voxels)			
Associated Network	Coordinates	Cluster Peak Coordinates (MNI)			
	(MNI)				
BA 25	-5,25,-10	664; L DLPFC (BA 9); -16,+54,+30			
Subgenual Cingulate		299; L Paracingulate Gyrus (BA 32);			
Cortex		-8,+48,+10			
Reward Network seed		282; L Orbitolfrontal Cortex; (BA 47);			
(Figure 4; Row 1)		-38,+26,-8			
		274; R Paracingulate Gyrus (BA 32); +8,+50,+8			
		252; R DLPFC (BA 9); +6,+56,+10			
BA 10/14	-1,55,-3	452; L temporal pole (BA 38); -32,10,-30			
Ventromedial	d l	312; L middle temporal gyrus, posterior division (BA 21); -56,-26,			
Prefrontal Cortex		186; R parahippocampal gyrus, posterior division (BA 36); 24,-28,-			
Anterior Default Mode Network seed		18			
(Figure 4; Row 2)		168; R hippocampus; 26,-20,-16			
(Figure 4, Now 2)		167; L frontal orbital cortex (BA 47); -28,22,			
		-22			
BA 24	-5,0,30	436; R paracingulate cortex/anterior PFC (BA 10); 6,48,10			
Ventral Anterior		327; R anterior frontal pole (BA 10); 20,58,4			
Cingulate Cortex		312; R dorsal ACC (BA32); 0,38,10			
Executive Control Network seed		298; L dorsal ACC (BA 32); -6,46,14			
(Figure 4, Row 3)		264; L anterior frontal pole (BA 10); -18,58,-2			
BA 23/31	-1,-61,38	684; L Precuneous Cortex (BA 31); -4,-54,48			
Posterior Cingulate	1	590; R superior parietal lobule (BA 7); 28,-48,58			
Cortex		390; L superior pariental lobule (BA 7); -28,-46,58			
Posterior Default Mode Network seed		259; L postcentral gyrus (BA 40); -42,-30,42			
(Figure 4; Row 4)		186; L lateral occipital cortex (BA 7); -22,-68,40			
BA 32	-1,22,35	1868; R frontal pole (BA 10); 28,48,18.			
		1311; R middle frontal gyrus (BA 8); 36,16,46			

Dorsal Anterior	622; R anterior cingulate gyrus (BA 24); 2,34,14
Cingulate Cortex	506; R precentral gyrus; 40,4,48
Salience Network seed	278; R paracingulate gyrus (BA 10); 12,42,16
(Figure 4, Row 5)	

$\textbf{Supplementary Table 4S} \ \ \text{Behavioral Assessments Following N$_2$O/Placebo Inhalation}$

	Nitrous Oxide Timepoints			Placebo Timepoints		
	0 (baseline)	2 hour post	24 hour post	0 (baseline)	2 hour post	24 hour post
n						
controls	16	16	16	17	17	17
TRD	14	14	14	14	14	14
Treatment = N2O (%)						
controls	16 (100.0)	16 (100.0)	16 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)
TRD	14 (100.0)	14 (100.0)	14 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)
Sex = Female (%)						
controls	7 (43.8)	7 (43.8)	7 (43.8)	7 (41.2)	7 (41.2)	7 (41.2)
TRD	4 (28.6)	4 (28.6)	4 (28.6)	4 (28.6)	4 (28.6)	4 (28.6)
MADRS (mean, SD)						
controls	0.21 (0.58)	0.29 (0.47)	0.43 (1.09)	1.24 (2.36)	1.47 (2.58)	0.88 (2.55)
TRD	27.64 (15.18)	16.21 (12.39)	18.00 (13.36)	30.21 (7.90)	17.93 (10.62)	16.29 (10.31)
HAMD-17 (mean, SD)						
controls	0.43 (0.76)	0.21 (0.58)	0.71 (1.33)	1.24 (1.99)	1.71 (2.39)	1.12 (2.39)
TRD	17.14 (8.87)	11.23 (6.67)	11.64 (7.35)	19.07 (4.25)	11.93 (5.77)	11.71 (5.89)
QIDS (mean, SD)						
controls	2.36 (2.62)	1.71 (1.54)	1.50 (1.51)	2.47 (1.50)	1.94 (1.20)	1.65 (1.32)
TRD	13.43 (6.32)	8.93 (6.16)	9.93 (5.97)	14.64 (4.22)	9.64 (5.46)	9.29 (5.88)
CADSS (mean, SD)						
controls	0.14 (0.36)	0.07 (0.27)	0.00 (0.00)	0.29 (1.21)	0.76 (2.91)	0.76 (2.66)
TRD	1.91 (4.30)	1.00 (3.46)	0.93 (2.64)	0.93 (2.92)	1.38 (3.48)	0.50 (1.87)
POMS (mean, SD)						
controls	30.79 (9.82)	28.69 (10.61)	27.43 (9.98)	31.80 (8.28)	27.50 (7.70)	26.75 (7.09)
TRD	55.00 (23.61)	34.00 (18.00)	37.64 (18.25)	55.38 (18.50)	35.15 (16.00)	36.15 (15.77)
BPRS (mean, SD)						
controls	24.21 (0.58)	24.14 (0.53)	24.29 (0.73)	25.06 (2.28)	24.94 (2.01)	25.12 (2.12)
TRD	37.08 (8.61)	31.14 (6.97)	32.38 (7.16)	38.29 (5.37)	31.14 (4.83)	31.93 (5.47)